Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 439 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Eisai Inc. Clear all
Completed Phase 2 Interventional

The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment

NCT00103948
View directory record Official record
Conditions
Cognitive Impairment
Interventions
Aricept
Drug
Lead sponsor
Eisai Limited
Industry
Eligibility
25 Years to 70 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Maywood, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

NCT01761266
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Lenvatinib, Sorafenib
Drug
Lead sponsor
Eisai Limited
Industry
Eligibility
18 Years and older
Enrollment
954 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
21
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment

NCT03443063
View directory record Official record
Conditions
Renal Impairment
Interventions
Lemborexant
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

NCT03245151
View directory record Official record
Conditions
Recurrent and Refractory Solid Tumors
Interventions
Lenvatinib, Everolimus
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years to 21 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 15, 2026, 4:21 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).

NCT04949256
View directory record Official record
Conditions
Metastatic Esophageal Squamous Cell Carcinoma
Interventions
Pembrolizumab, Lenvatinib, Cisplatin, 5-FU, Oxaliplatin, Leucovorin, Levoleucovorin, Paclitaxel
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
863 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
15
States / cities
Duarte, California • Washington D.C., District of Columbia • Louisville, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 4 Interventional

Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial

NCT00203450
View directory record Official record
Conditions
Obesity
Interventions
Zonegran, Placebo
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
19 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Results available

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

NCT01269346
View directory record Official record
Conditions
Breast Cancer
Interventions
Eribulin Mesylate
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
26
States / cities
Denver, Colorado • Davie, Florida • Jacksonville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 15, 2026, 4:21 PM EDT
Terminated Phase 2 Interventional Results available

Low-Dose Decitabine in Myelodysplastic Syndrome Post Azacytidine Failure

NCT00113321
View directory record Official record
Conditions
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Interventions
Decitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects

NCT02222324
View directory record Official record
Conditions
Healthy Subjects
Interventions
Placebo, E2609, Moxifloxacin
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Results available

A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents

NCT01161524
View directory record Official record
Conditions
Epilepsy
Interventions
Perampanel, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 18 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
11
States / cities
Aurora, Colorado • Gulf Breeze, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of Perampanel in Healthy Subjects

NCT01396577
View directory record Official record
Conditions
Healthy
Interventions
perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 4, 2012 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 3 Interventional Results available

E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers

NCT00236197
View directory record Official record
Conditions
Heartburn
Interventions
rabeprazole sodium, placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
19 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Nov 11, 2009 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Results available

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome

NCT00570128
View directory record Official record
Conditions
Down Syndrome
Interventions
Donepezil HCl, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 4 Interventional Results available

A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment

NCT00934375
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Aricept (donepezil hydrochloride), placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
145 participants
Timeline
2006 – 2007
U.S. locations
49
States / cities
Alabaster, Alabama • Peoria, Arizona • Sun City, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Oct 15, 2026, 4:21 PM EDT
Terminated Phase 1 Interventional Results available

Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101

NCT04144140
View directory record Official record
Conditions
Lymphoma, Advanced Solid Tumors
Interventions
E7766
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
New Haven, Connecticut • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants

NCT07308236
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2086
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 15, 2026, 4:21 PM EDT
Terminated Phase 1 Interventional

A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome

NCT00282399
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Subcutaneous Decitabine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Tucson, Arizona • Tampa, Florida • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 2Phase 3 Interventional

Study of AQUAVAN® Injection (AQUAVAN; Fospropofol Disodium) for Sedation During Colonoscopy

NCT00125424
View directory record Official record
Conditions
Colonoscopy, Colonic Polyps
Interventions
AQUAVAN® (fospropofol disodium) Injection, Midazolam HCl
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
20
States / cities
Huntsville, Alabama • Phoenix, Arizona • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2008 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 1 Interventional Results available

A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma

NCT03006926
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
lenvatinib, pembrolizumab (200 mg)
Drug
Lead sponsor
Eisai Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
San Francisco, California • Santa Monica, California • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures.

NCT00327392
View directory record Official record
Conditions
Procedural Sedation
Interventions
AQUAVAN® (fospropofol disodium) Injection
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Phoenix, Arizona • Jacksonville, Florida • Louisville, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 2 Interventional

An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis

NCT01146509
View directory record Official record
Conditions
Migraine Headache
Interventions
Aricept (donepezil hydrochloride)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
4
States / cities
Chicago, Illinois • Springfield, Missouri • Mount Vernon, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma

NCT00715793
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Decitabine, Temozolomide, biopsy
Drug · Procedure
Lead sponsor
Hussein Tawbi
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

NCT01378416
View directory record Official record
Conditions
Leukemia
Interventions
Decitabine (Dacogen)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 15, 2026, 4:21 PM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

NCT01335009
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
MORAb-004 (monoclonal antibody)
Biological
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
20
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 15, 2026, 4:21 PM EDT